These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 24361415)
1. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Ioannou GN; Beste LA; Green PK Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1371-80. PubMed ID: 24361415 [TBL] [Abstract][Full Text] [Related]
2. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130 [TBL] [Abstract][Full Text] [Related]
3. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA; Green PK; Ioannou GN Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739 [TBL] [Abstract][Full Text] [Related]
4. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Backus LI; Belperio PS; Shahoumian TA; Cheung R; Mole LA Aliment Pharmacol Ther; 2014 Jan; 39(1):93-103. PubMed ID: 24206566 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. Park C; Jiang S; Lawson KA J Clin Pharm Ther; 2014 Feb; 39(1):14-24. PubMed ID: 24237070 [TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Harrington PR; Zeng W; Naeger LK Hepatology; 2012 Apr; 55(4):1048-57. PubMed ID: 22095516 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132 [TBL] [Abstract][Full Text] [Related]
12. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289 [TBL] [Abstract][Full Text] [Related]
14. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799 [TBL] [Abstract][Full Text] [Related]
15. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]. Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z; Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. Bichoupan K; Tandon N; Martel-Laferriere V; Patel NM; Sachs D; Ng M; Schonfeld EA; Pappas A; Crismale J; Stivala A; Khaitova V; Gardenier D; Linderman M; Olson W; Perumalswami PV; Schiano TD; Odin JA; Liu LU; Dieterich DT; Branch AD World J Hepatol; 2017 Apr; 9(11):551-561. PubMed ID: 28469811 [TBL] [Abstract][Full Text] [Related]
17. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. Bonnet D; Guivarch M; Bérard E; Combis JM; Remy AJ; Glibert A; Payen JL; Metivier S; Barange K; Desmorat H; Palacin A; Nicot F; Abravanel F; Alric L World J Hepatol; 2014 Sep; 6(9):660-9. PubMed ID: 25276282 [TBL] [Abstract][Full Text] [Related]
18. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. Macartney MJ; Irish D; Bridge SH; Garcia-Diaz A; Booth CL; McCormick AL; Labbett W; Smith C; Velazquez C; Tanwar S; Trembling P; Jacobs M; Dusheiko G; Rosenberg W; Haque T Antiviral Res; 2014 May; 105():112-7. PubMed ID: 24594347 [TBL] [Abstract][Full Text] [Related]
19. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Harris JB; Ward MA; Schwab P Am Health Drug Benefits; 2015 Feb; 8(1):22-8. PubMed ID: 25964830 [TBL] [Abstract][Full Text] [Related]